BioMarin Pharmaceutical
(NASDAQ) BMRN
BioMarin Pharmaceutical Financials at a Glance
Market Cap
$10.69B
Revenue (TTM)
$3.22B
Net Income (TTM)
$348.90M
EPS (TTM)
$1.78
P/E Ratio
31.20
Dividend
$0.00
Beta (Volatility)
0.73 (Low)
Dividend
$0.00
Beta (Volatility)
0.73 (Low)
Price
$55.75
Volume
14,793
Open
$55.16
Price
$55.75
Volume
14,793
Open
$55.16
Previous Close
$55.59
Daily Range
$55.16 - $56.03
52-Week Range
$50.76 - $73.18
Dividend
$0.00
Beta (Volatility)
0.73 (Low)
Price
$55.75
Volume
14,793
Open
$55.16
Previous Close
$55.59
Daily Range
$55.16 - $56.03
52-Week Range
$50.76 - $73.18
BMRN News
BMRN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BioMarin Pharmaceutical
Industry
Biotechnology
Sector
Health CareEmployees
3,221
CEO
Alexander Hardy
Website
www.biomarin.comHeadquarters
San Rafael, CA 94901, US
BMRN Financials
Key Financial Metrics (TTM)
Gross Margin
77%
Operating Margin
17%
Net Income Margin
11%
Return on Equity
6%
Return on Capital
8%
Return on Assets
5%
Earnings Yield
3.21%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$10.69B
Shares Outstanding
192.32M
Volume
14.79K
Short Interest
0.00%
Avg. Volume
2.17M
Financials (TTM)
Gross Profit
$2.48B
Operating Income
$533.48M
EBITDA
$572.94M
Operating Cash Flow
$827.99M
Capital Expenditure
$103.04M
Free Cash Flow
$724.96M
Cash & ST Invst.
$1.56B
Total Debt
$642.87M
BioMarin Pharmaceutical Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$874.57M
+17.0%
Gross Profit
$579.47M
-5.2%
Gross Margin
66.26%
N/A
Market Cap
$10.69B
N/A
Market Cap/Employee
$3.52M
N/A
Employees
3,040
N/A
Net Income
$46.57M
-137.3%
EBITDA
$3.94M
-102.0%
Quarterly Fundamentals
Net Cash
$917.74M
+71.5%
Accounts Receivable
$908.21M
+37.5%
Inventory
$1.30B
+5.4%
Long Term Debt
$634.19M
+6.6%
Short Term Debt
$8.69M
+14.7%
Return on Assets
4.59%
N/A
Return on Invested Capital
7.81%
N/A
Free Cash Flow
$58.92M
-64.4%
Operating Cash Flow
$99.64M
-46.3%